Gavi Endorses WHO-Prequalified RSV Maternal Vaccine to Avert Infant Pneumonia Deaths
A maternal vaccine protecting newborns against Respiratory Syncytial Virus (RSV) received WHO prequalification, marking a milestone in infant mortality prevention.
Geneva: Gavi welcomed WHO prequalification of the first multi-dose maternal vaccine combating RSV, the second-highest cause of infant mortality behind malaria.
Maternal immunization transmits protective antibodies transplacentally, defending babies throughout their first six critical months of life.
About Pediatric Bureau
Pediatric Bureau is a senior correspondent at Greenline News covering health and related global events.
View all articles by Pediatric BureauComments (2)
Excellent reporting on this issue. It's crucial that we stay informed about these developments.
I wonder how this will affect the local communities in the long run. Would love to see a follow-up article.